Q4 2025 Getinge AB Earnings Call Transcript

Jan 27, 2026 / 09:00AM GMT

Release Date Price: €18.79 (-5.70%)

Transcript

Key Points

Positve

Getinge AB (GNGBF) achieved record high organic sales in Q4 2025, with a 1.2% organic increase in net sales.
The company has made significant progress in quality remediation, reducing the number of field actions in relation to sales.
Getinge AB (GNGBF) launched several new products, including the Aquadis 44 washer-disinfector and Automatiq solutions, enhancing their product portfolio.
The company maintains a strong financial position with a leverage of 1.5 times adjusted EBITDA, well below their internal threshold.
Getinge AB (GNGBF) continues to focus on high-margin products and recurring revenue, which now make up a significant portion of total sales.

Negative

Adjusted gross and EBITA margins were down in Q4 2025 due to strong headwinds from currency and tariffs.
The Life Science segment experienced a decline in organic order intake, particularly in the WIS and Bio-Processing businesses.
Tariffs and currency fluctuations resulted in a significant drag on adjusted EBITA, with over SEK 1 billion impact for the full year.
The company faces ongoing geopolitical and FX headwinds, which are expected to continue into 2026.
There are delays in the Cardiosave product launch in the US due to critical component shortages, impacting sales potential.

Operator

Welcome to the Getinge Q4 report 2025. (Operator Instructions)

Now I will hand the conference over to the speakers, CEO, Mattias Perjos; and CFO, Agneta Palmer. Please go ahead.

Mattias Perjos

Getinge AB - President, Chief Executive Officer, Director

Thank you very much, and welcome, everyone to today's earnings call here with me, I have our CFO, Agneta Palmer. We will start the conference today with our performance in the fourth quarter and then reflect a bit on the full year and our expectations for 2026 and onwards before ending with a Q&A.

So we can move directly to page number 2, please. So let's first look at the development of our longer-term strategic KPIs. You can see that we continue to clearly track in line with our plans to increase the share of sales from recurring revenue, accelerating the share of sales from high-margin products like our Paragonix offering, our ECLS portfolio, the consumables with Infection Controls and also BetaBags inside our Sterile Transfer segment in Life Science. This is all supported by solid and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.